Advertisement
Australia markets closed

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • AUD/USD

    0.6503
    +0.0003 (+0.04%)
     

  • OIL

    82.70
    -0.11 (-0.13%)
     

  • GOLD

    2,329.60
    -8.80 (-0.38%)
     

  • Bitcoin AUD

    99,220.44
    -3,484.48 (-3.39%)
     

  • CMC Crypto 200

    1,393.30
    -30.80 (-2.16%)
     

  • AUD/EUR

    0.6070
    0.0000 (0.00%)
     

  • AUD/NZD

    1.0945
    +0.0003 (+0.03%)
     

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    18,088.70
    -48.95 (-0.27%)
     

  • Hang Seng

    17,201.27
    0.00 (0.00%)
     

  • NIKKEI 225

    37,932.95
    -527.13 (-1.37%)
     

CorMedix Inc. to Host Regulatory Update Conference Call

CorMedix, Inc.
·1-min read

BERKELEY HEIGHTS, N.J., March 08, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will host a conference call relating to a regulatory update for DefenCath™ at 8:30am ET on March 9, 2021.

Tuesday, March 9th @ 8:30am ET

Domestic:

877-423-9813

International:

201-689-8573

Conference ID:

13717520

Webcast:

Webcast Link

About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product DefenCath™, a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. DefenCath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product, which provides an additional five years of marketing exclusivity, which will be added to the five years granted to a New Chemical Entity upon approval of the NDA. CorMedix also intends to develop DefenCath as a catheter lock solution for use in oncology and total parenteral nutrition patients. It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrogels. The Company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers. Neutrolin® is CE Marked and marketed in Europe and other territories as a medical device. For more information, visit: www.cormedix.com.

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
(617) 430-7576